🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Endometrial Clear Cell Adenocarcinoma

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers NCT05049538n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Biospecimen Collection, Liquid Biopsy, Pap Smear Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601Phase 2138 sites📍 Birmingham📍 Athens📍 Augusta National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) NCT06023862Phase 227 sites📍 Clayton📍 Waratah📍 Melbourne Yonsei University · Tests: Dostarlimab, Bevacizumab, Doxorubicin, Gemcitabine, Paclitaxel A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347Phase 216 sites📍 Los Angeles📍 New Orleans📍 Grand Rapids MacroGenics · Tests: Lorigerlimab A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776Phase 1, Phase 280 sites📍 Tampa📍 Atlanta📍 Chicago Novartis Pharmaceuticals · Tests: Tulmimetostat, Enzalutamide Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. NCT07303387Phase 24 sites📍 Villejuif📍 Bordeaux📍 Lyon Gustave Roussy, Cancer Campus, Grand Paris · Tests: Valemetostat Tosylate Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin NCT06677190Phase 22 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Belzutifan Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer NCT05950464Phase 114 sites📍 Augusta📍 Chicago📍 Iowa City National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance I… Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer NCT07871838NA1 site📍 Montreal McGill University Health Centre/Research Institute of the M… · Tests: Hypo fractionated RT Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 111 sites📍 Detroit📍 St Louis📍 Charlotte Sairopa B.V. · Tests: ADU-1805, Pembrolizumab A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites📍 Buffalo📍 Houston Roswell Park Cancer Institute · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire A… Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer NCT03422198Phase 35 sites📍 Palo Alto📍 Maywood📍 Houston University of Utah · Tests: Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer NCT05542407Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Atezolizumab, ONC201
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy